Several brokerages have updated their recommendations and price targets on shares of Koninklijke Philips N.V. (NYSE: PHG) in the last few weeks:

  • 7/11/2017 – Koninklijke Philips N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Year to date, Philips’ shares have outperformed the Zacks categorized Electronic Product Miscellaneous industry’s average return. Philips has been generating strong profits, helped by a pick-up in sales, but the company sees increasingly uncertain business environment in the near future, particularly in the U.S. The company’s mature end markets seem weak, which could dampen overall growth. Also, Philips is under scrutiny from the FDA concerning a defibrillators dispute, which could impact its operations. Uncertainties like slowing government spending and events surrounding the ACA (Affordable Care Act) legislation are delaying hospitals’ capital spending, which could harm Philips’ operations. Also, prospects of the European healthcare market look muted. Philips’ near-term profitability is likely to be hurt by the sluggish growth prospects of the healthcare market on a global scale.”
  • 7/4/2017 – Koninklijke Philips N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $40.00 price target on the stock. According to Zacks, “Year to date, Philips’ shares have outperformed the Zacks categorized Electronic Product Miscellaneous industry’s average return. Philips has been generating strong profits, helped by a pick-up in sales, but the company sees increasingly uncertain business environment in the near future, particularly in the U.S. Nevertheless, Philips is enjoying great momentum in its HealthTech portfolio sales. The company’s profitability has also improved, owing to highly successful cost-productivity programs and higher volumes. Philips has implemented three performance improvement and change-initiative programs, and expects increased spending on healthcare and fitness to be a long-term growth driver. The company’s continuous investments in this segment and innovative product launches are adding to its strength. Its recent acquisition spree should also boost revenues in the near term.”
  • 7/3/2017 – Koninklijke Philips N.V. had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $37.00 price target on the stock.
  • 7/1/2017 – Koninklijke Philips N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Year to date, Philips’ shares have outperformed the Zacks categorized Electronic Product Miscellaneous industry’s average return. Philips has been generating strong profits, helped by a pick-up in sales, but the company sees increasingly uncertain business environment in the near future, particularly in the U.S. The company’s mature end markets seem weak, which could dampen overall growth. Also, Philips is under scrutiny from the FDA concerning a defibrillators dispute, which could impact its operations. However, Philips is enjoying great momentum in its HealthTech portfolio sales. The company’s profitability has also improved, owing to highly successful cost-productivity programs and higher volumes. Philips has implemented three performance improvement and change-initiative programs, and expects increased spending on healthcare and fitness to be a long-term growth driver. “
  • 6/21/2017 – Koninklijke Philips N.V. was downgraded by analysts at Natixis from a “buy” rating to a “neutral” rating.
  • 6/20/2017 – Koninklijke Philips N.V. was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating.
  • 6/7/2017 – Koninklijke Philips N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $40.00 price target on the stock. According to Zacks, “Over the past six months, Philips’ shares have outperformed the Zacks categorized Electronic Product Miscellaneous industry’s average return. Philips remains optimistic about the prospects of its Diagnosis & Treatment vertical on account of positive industry trends. Especially, Image-Guided Therapy and Ultrasound equipment sales are likely to act as major profit churners. Also, the company’s bolt-on acquisitions to boost its respiratory- and sleep-care portfolio are expected to boost inorganic growth. Philips has implemented three performance improvement and change-initiative programs, and expects increased spending on healthcare and fitness to be a long-term growth driver. However, on the flip side, the company sees increasingly uncertain business environment in the near future, particularly in the U.S. Philips’ mature end markets seem weak, which could dampen overall growth.”

Shares of Koninklijke Philips N.V. (NYSE PHG) opened at 36.49 on Tuesday. Koninklijke Philips N.V. has a 1-year low of $25.50 and a 1-year high of $38.21. The stock’s 50 day moving average is $35.89 and its 200 day moving average is $32.32. The firm has a market capitalization of $33.58 billion, a P/E ratio of 17.98 and a beta of 1.34.

Koninklijke Philips N.V. (NYSE:PHG) last posted its earnings results on Monday, April 24th. The technology company reported $0.20 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.20. The firm had revenue of $5.72 billion for the quarter, compared to the consensus estimate of $5.70 billion. Koninklijke Philips N.V. had a net margin of 6.67% and a return on equity of 9.80%. The company’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $0.03 EPS. Equities analysts predict that Koninklijke Philips N.V. will post $1.95 earnings per share for the current year.

Koninklijke Philips N.V. is a health technology company. The Company’s segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, and Lighting. The Company’s Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease.

Receive News & Ratings for Koninklijke Philips NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips NV and related companies with MarketBeat.com's FREE daily email newsletter.